Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma

被引:10
|
作者
Lin, Haoming [1 ]
Zhang, Rui [1 ]
Wu, Wenrui [1 ]
Lei, Liming [2 ]
机构
[1] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pancretobiliary Surg, Guangzhou 510120, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Cardiovasc Inst, Dept Intens Care,Unit Cardiovasc Surg,Lab South C, Guangzhou 510080, Guangdong, Peoples R China
关键词
Hepatocellular carcinoma; Sorafenib resistance; Transcription factors; Dysfunctional gene; Molecular mechanisms; DRUG-RESISTANCE; MESENCHYMAL TRANSITION; DOWN-REGULATION; UP-REGULATION; CANCER-CELLS; EXPRESSION; EFFICACY; SENSITIZES; IMMUNITY; PATHWAY;
D O I
10.1016/j.cancergen.2020.04.076
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Hepatocellular carcinoma (HCC) is an intractable disease because patients with HCC frequently develop sorafenib resistance after long-term chemotherapy. Although studies has demonstrated the availability of cumulative information on drug-resistant patients, little is known about the strategies and molecular mechanisms to reverse sorafenib resistance. Here, the present study identified critical mRNAs and transcription factors (TFs) associated with sorafenib resistance of HCC and evaluated the significance correlation between drug-resistant genes and TFs in comprehensive network for HCC xenografts mice. Methods: The expression profiles of mRNAs were compared between sorafenib-acquired resistant tissue and sorafenib sensitive tissue utilizing RNA-Seq data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Gene Ontology and KEGG pathway analysis were performed to investigate the biological function of significantly dysregulated mRNA. Furthermore, the Kaplan-Meier survival analyses were performed to evaluate the effect of mRNA on over survival. Subsequently, TFs were predicted using TRANSFAC and TF-mRNA regulatory networks were visualized using cytoscape software. Results: A total of 827 mRNAs were found to be differentially expressed in sorafenib-acquired resistant tissue compared with control. Thereafter, the results of functional enrichment analysis showed the dysregulated mRNAs involved in drug-resistant signaling pathway, including MAPK, JAK-STAT, TGF-beta and drug-metabolism cytochrome P450 signaling pathway. CDK1, CDKN1A and TAPBP might serve as prognostic signature of resistance of HCC to sorafenib according to the survival analysis. Furthermore, TF-mRNA networks were constructed. There were 18 TFs were predicted to regulate differentially expressed mRNAs, which play an essential role in the regulation of dysfunctional gene networks. NFKB1 was presented in the TF-mRNA networks as the node with the highest degree and MYC was predicted as prognostic TF in drug resistance of HCC Conclusions: Taken together, our findings showed that novel mRNAs and TFs, which served as critical biomarkers to predict survival and therapeutic targets of resistance to sorafenib in HCC. Furthermore, we constructed the TF-mRNA networks, which provides valuable theoretical references to further evaluate the molecular mechanisms of resistance to sorafenib in HCC. (C) 2020 Published by Elsevier Inc.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 50 条
  • [1] Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms
    Dahiya, Mandeep
    Dureja, Harish
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (05) : 286 - 301
  • [2] Mechanisms of sorafenib resistance in hepatocellular carcinoma
    Liang, Yuanjing
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (08)
  • [3] Molecular mechanisms of HCG18 in the sorafenib resistance of hepatocellular carcinoma
    Li, Heping
    Hu, Jie
    Qiu, Lijie
    Wu, Yijiang
    Zhong, Baiyin
    Ye, Rong
    Xie, Binhui
    ANTI-CANCER DRUGS, 2024, 35 (01) : 55 - 62
  • [4] Elucidation of the molecular mechanisms mediating sorafenib-resistance in Hepatocellular carcinoma
    Vishnoi, Kanchan
    Ke, Rong
    Kumar, Randhir
    Viswakarma, Navin
    Rana, Ajay
    Rana, Basabi
    CANCER RESEARCH, 2020, 80 (16)
  • [5] Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
    Zhai, Bo
    Sun, Xue-Ying
    WORLD JOURNAL OF HEPATOLOGY, 2013, 5 (07) : 345 - 352
  • [6] Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
    Berasain, Carmen
    GUT, 2013, 62 (12) : 1674 - 1675
  • [7] Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
    Bo Zhai
    Xue-Ying Sun
    World Journal of Hepatology, 2013, (07) : 345 - 352
  • [8] Comprehensive Analysis of the Sorafenib-Associated Druggable Targets on Differential Gene Expression and ceRNA Network in Hepatocellular Carcinoma
    Fu, Zhi
    Yang, Guang
    Wang, Tiezheng
    Gao, Daming
    Lin, Dongdong
    Liu, Xiaoni
    JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY, 2023, 42 (04) : 47 - 60
  • [9] Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors Associated with Hepatocellular Carcinoma
    Tian, Yichen
    Lei, Yongrong
    Fu, Yuna
    Sun, Heng
    Wang, Jianhua
    Xia, Feng
    CURRENT CANCER DRUG TARGETS, 2022, 22 (06) : 454 - 462
  • [10] The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
    Weiwei Tang
    Ziyi Chen
    Wenling Zhang
    Ye Cheng
    Betty Zhang
    Fan Wu
    Qian Wang
    Shouju Wang
    Dawei Rong
    F. P. Reiter
    E. N. De Toni
    Xuehao Wang
    Signal Transduction and Targeted Therapy, 5